Literature DB >> 25066495

Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis.

Sung-Wan Kim1, Miriam R Schäfer2, Claudia M Klier3, Michael Berk4, Simon Rice5, Kelly Allott5, Cali F Bartholomeusz6, Sarah L Whittle6, Eleanor Pilioussis6, Christos Pantelis6, Patrick D McGorry5, G Paul Amminger7.   

Abstract

Cognitive symptoms and impairment are central to schizophrenia and often an early sign of this condition. The present study investigated biological correlates of cognitive symptoms and performance in individuals at ultra-high risk (UHR) for psychosis. The study sample comprised 80 neuroleptic-naïve UHR individuals aged 13-25 years. Associations among erythrocyte membrane fatty acid levels, measured by gas chromatography, and cognitive functioning were investigated in UHR patients. Subjects were divided into terciles based on their scores on the cognitive factor of the Positive and Negative Syndrome Scale. The Zahlen-Verbindungs Test (ZVT) (the number-combination test) was also used as a measure of information-processing speed. Exploratory analysis was conducted to investigate the relationship between membrane fatty acid levels with the size of the intracranial area (ICA), a neurodevelopmental measure relevant to schizophrenia, in half of subjects (n=40) using magnetic resonance imaging. The adjusted analysis revealed that omega-9 eicosenoic and erucic acid levels were significantly higher, but omega-3 docosahexaenoic acid levels were significantly lower, in the cognitively impaired than in the cognitively intact group. We found a significant negative association of eicosenoic, erucic, and gamma-linoleic acids with ZVT scores. A negative association between ICA and membrane levels of eicosenoic acid was also found. This is the first study to demonstrate the relationship between membrane fatty acids and cognitive function in neuroleptic-naïve subjects at UHR for psychosis. The study findings indicate that abnormalities in membrane fatty acids may be associated with the neurodevelopmental disruption associated with the cognitive impairments of individuals at UHR for psychosis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognitive symptom; Eicosenoic acid; Intracranial area; Membrane fatty acid; Schizophrenia; Ultra-high risk

Mesh:

Substances:

Year:  2014        PMID: 25066495     DOI: 10.1016/j.schres.2014.06.032

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

Review 1.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

2.  Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia.

Authors:  Mohammad M Khan
Journal:  World J Psychiatry       Date:  2022-06-19

3.  Alterations in levels and ratios of n-3 and n-6 polyunsaturated fatty acids in the temporal cortex and liver of vervet monkeys from birth to early adulthood.

Authors:  Leslie R Miller; Matthew J Jorgensen; Jay R Kaplan; Michael C Seeds; Elaheh Rahbar; Timothy M Morgan; Andrea Welborn; Sarah M Chilton; Julianne Gillis; Austin Hester; Mae Rukstalis; Susan Sergeant; Floyd H Chilton
Journal:  Physiol Behav       Date:  2015-12-17

4.  Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.

Authors:  Philip R Szeszko; Robert K McNamara; Juan A Gallego; Anil K Malhotra; Usha Govindarajulu; Bart D Peters; Delbert G Robinson
Journal:  Schizophr Res       Date:  2021-01-11       Impact factor: 4.939

5.  Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study.

Authors:  Sung-Wan Kim; Min Jhon; Jae-Min Kim; Stefan Smesny; Simon Rice; Michael Berk; Claudia M Klier; Patrick D McGorry; Miriam R Schäfer; G Paul Amminger
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

Review 6.  Precision Nutrition and Omega-3 Polyunsaturated Fatty Acids: A Case for Personalized Supplementation Approaches for the Prevention and Management of Human Diseases.

Authors:  Floyd H Chilton; Rahul Dutta; Lindsay M Reynolds; Susan Sergeant; Rasika A Mathias; Michael C Seeds
Journal:  Nutrients       Date:  2017-10-25       Impact factor: 5.717

7.  Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations.

Authors:  C Tessier; K Sweers; A Frajerman; H Bergaoui; F Ferreri; C Delva; N Lapidus; A Lamaziere; J P Roiser; M De Hert; P Nuss
Journal:  Transl Psychiatry       Date:  2016-10-04       Impact factor: 6.222

Review 8.  Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.

Authors:  Mei-Chi Hsu; Yung-Sheng Huang; Wen-Chen Ouyang
Journal:  Lipids Health Dis       Date:  2020-07-03       Impact factor: 3.876

Review 9.  Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?

Authors:  Ariel Frajerman; Linda Scoriels; Oussama Kebir; Boris Chaumette
Journal:  Int J Mol Sci       Date:  2021-06-26       Impact factor: 5.923

10.  Validation of the Korean version of the 16-Item Prodromal Questionnaire in a Non-Help-Seeking College Population.

Authors:  Sung-Wan Kim; Young-Chul Chung; Young-Shin Kang; Jae-Kyeong Kim; Ji-Eun Jang; Min Jhon; Ju-Yeon Lee; Jae-Min Kim; Il-Seon Shin; Jin-Sang Yoon
Journal:  Psychiatry Investig       Date:  2017-11-29       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.